OncLive TV

Benjamin Garmezy, MD, discusses the treatment of patients with cancer in the community care setting, highlighting the need to include those from this population in enrollment to clinical trials.

Patrick Boland, MD, discusses the development of therapeutic strategies targeting KRAS G12C mutations in colorectal cancer.

Faith E. Davies, MD, discusses strategies for rectifying global gaps and addressing unmet needs in multiple myeloma care.

Tian Zhang, MD, MHS, discusses the evolution of the use of belzutifan in renal cell carcinoma, highlighting which key oncologists have been involved in this research.

Alan Tan, MD, discusses the ongoing potential utility of circulating tumor DNA in patients with renal cell carcinoma and highlights how this approach is being used in his own practice.

Elizabeth Buchbinder, MD, discusses the investigation of treatment with nivolumab maintenance therapy in patients with melanoma who experienced severe immune-related adverse effects associated with combination therapy with nivolumab and ipilimumab.

Javier Cortés, MD, PhD, discusses primary outcomes and safety findings from a pooled analysis of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who have brain metastases.

Joshua Richter, MD, discusses how bispecific antibodies fit into the current treatment armamentarium for patients with multiple myeloma, highlighting his presentation from the 41st Annual CFS®.

Adrienne Phillips, MD, MPH, discusses the management of toxicities associated with CAR T-cell therapy across hematologic malignancies.

Haejin In, MD, MPH, MBA, FACS, FSSO, discusses the increased incidence of gastric cancer in minority patient populations, highlighting the disparities that lead to these patient outcomes in the United States.

Kathleen N. Moore, MD, MS, discusses continued efforts to target the immune system in ovarian cancer through the use of immunotherapy, as well as alternative strategies being explored in this tumor type.

Md Kamrul Hasan, PhD, discusses the preclinical efficacy and safety of ROR1-specific CAR T-cells in a preclinical mouse model of chronic lymphocytic leukemia.

Brett L. Ecker, MD, discusses the evaluation of the microbiome in pancreatic cancer, highlighting remaining questions and future steps for research.

Kevin Kalinsky, MD, MS, discusses key takeaways from the 2023 Bridging the Gaps in Breast Cancer meeting, highlighting questions that continue to persist in the treatment of breast cancer.

Reva K Basho, MD, discusses the use of antibody-drug conjugates across the spectrum of breast cancer subtypes at the 2023 Bridging the Gaps in Breast Cancer meeting.

Christopher M. Gallagher, MD, discusses treatment sequencing considerations with antibody-drug conjugates in patients with HER2-low metastatic breast cancer.

Andrew Laccetti, MD, MS, discusses phase 1 findings from a phase 1/2 trial investigating masofaniten in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.

Robert A. Anders, MD, PhD, discusses the rationale for investigating the use of tivumecirnon in patients with non–small cell lung cancer, as well as interim data from the dose-expansion portion of the phase 1/2 FLX475-02 study of this agent alone and in combination with pembrolizumab.

Yara Abdou, MD, discusses findings from the phase 2 MAINTAIN trial in patients with HER2-negative metastatic breast cancer, as well as the clinical implications of these trial results.

Komal Jhaveri, MD, FACP, discusses unmet needs for patients with breast cancer, as well as ways to address these needs through discussion and collaboration.

Vamsidhar Velcheti, MD, discusses the significance of the FDA approval of the ROS1 TKI repotrectinib in patients with ROS1-positive metastatic non–small cell lung cancer.

Alison K. Conlin, MD, discusses the importance of targeting central nervous system metastases in the treatment of patients with breast cancer, highlighting ongoing treatment investigations for this population.

Terry P. Mamounas, MD, discusses surgical de-escalation strategies in the treatment of patients with HER2-positive breast cancer.

Aditya Bardia, MD, MPH, discusses the continued investigation of oral selective estrogen receptor degraders in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Daneng Li, MD, discusses considerations when choosing between treatment with immuno-oncology-based combination regimens or single-agent TKIs in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma, highlighting which patient and disease factors influence these decisions.

Shanu Modi, MD, discusses updated survival data from the phase 3 DESTINY-Breast04 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with HER2-low metastatic breast cancer.

Joshua K. Sabari, MD, discusses the ongoing phase 2 EVOKE-2 trial investigating sacituzumab govitecan-hziy in non– small cell lung cancer; emerging data on antibody-drug conjugates in the second– or first-line treatment setting; and the planned phase 3 EVOKE-03 trial of sacituzumab govitecan plus pembrolizumab as a frontline treatment.

Howard S. Hochster, MD, discusses the importance of clinical trial participation for patients with cancer and highlights the use of precision medicine across the treatment armamentarium.

Benjamin Philip Levy, MD, discusses the ongoing development of the TROP-2 directed antibody-drug conjugates sacituzumab govitecan-hziy and datopotamab deruxtecan in non–small cell lung cancer, their different toxicity profiles, as well as the potential categorization of emerging ADCs as onco-directed therapies in this patient population.

Hossein Borghaei, DO, MS, discusses the importance of determining the most suitable treatment for patients with non–small cell lung cancer through the use of biomarker testing.